title: miR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway.
abstract: The PI3K/Akt signaling pathway is frequently activated in various human cancer types and plays essential roles in development and progression of cancers. Multiple regulators, such as phosphatase and tensin homolog (PTEN) and PH domain leucine rich repeat protein phosphatases (PHLPP), have also found to be involved in suppression of the PI3K/Akt signaling pathway. However, how suppressive effects mediated by these regulators are concomitantly disrupted in cancers, which display constitutively activated PI3K/Akt signaling, remains puzzling. In the present study, we reported that the expression of miR-93 was markedly upregulated in glioma cell lines and clinical glioma tissues. Statistical analysis revealed that miR-93 levels significantly correlated with clinicopathologic grade and overall survival in gliomas. Furthermore, we found that overexpressing miR-93 promoted, but inhibition of miR-93 reduced, glioma cell proliferation and cell-cycle progression. We demonstrated that miR-93 activated PI3K/Akt signaling through directly suppressing PTEN, PHLPP2 and FOXO3 expression via targeting their 3'UTRs. Therefore, our results suggest that miR-93 might play an important role in glioma progression and uncover a novel mechanism for constitutive PI3K/Akt activation in gliomas.
authors.affiliation: Department of Pathophysiology, Guangzhou Medical University, Guangzhou 510182, China.|State Key Laboratory of Oncology in Southern China, Department of Experimental Research, Cancer Centre, Sun Yat-sen University, Guangzhou 510060, China.
authors.forename: Lili
authors.initials: L
authors.lastname: Jiang
authors.affiliation: Department of the Central Laboratory, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou 510080, China.
authors.forename: Chanjuan
authors.initials: C
authors.lastname: Wang
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Experimental Research, Cancer Centre, Sun Yat-sen University, Guangzhou 510060, China.
authors.forename: Fangyong
authors.initials: F
authors.lastname: Lei
authors.affiliation: Laboratory of Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
authors.forename: Longjuan
authors.initials: L
authors.lastname: Zhang
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Experimental Research, Cancer Centre, Sun Yat-sen University, Guangzhou 510060, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors.forename: Aibin
authors.initials: A
authors.lastname: Liu
authors.affiliation: Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors.forename: Geyan
authors.initials: G
authors.lastname: Wu
authors.affiliation: Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors.forename: Jinrong
authors.initials: J
authors.lastname: Zhu
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Experimental Research, Cancer Centre, Sun Yat-sen University, Guangzhou 510060, China.
authors.forename: Libing
authors.initials: L
authors.lastname: Song
mesh_terms: D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002453:Cell Cycle / Q000502:physiology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000502:physiology; D005910:Glioma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D011379:Prognosis; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D015398:Signal Transduction; D015854:Up-Regulation
chemical_list: C543350:MIRN93 microRNA, human; D035683:MicroRNAs; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt
keywords: PI3K/Akt; gliomas; miR-93
references.citation: Cell. 2011 Jan 21;144(2):187-99
references.pmid: 21241890
references.citation: Mol Cell Biol. 2002 Apr;22(7):2111-23
references.pmid: 11884599
references.citation: Front Oncol. 2012 Feb 20;2:15
references.pmid: 22649777
references.citation: Hepatogastroenterology. 2012 Nov-Dec;59(120):2367-73
references.pmid: 22773266
references.citation: Oncogene. 1998 Apr 30;16(17):2259-64
references.pmid: 9619835
references.citation: EMBO J. 1996 Dec 2;15(23):6541-51
references.pmid: 8978681
references.citation: Nat Commun. 2012;3:1000
references.pmid: 22893124
references.citation: Mol Cancer. 2014;13:51
references.pmid: 24606633
references.citation: J Immunol. 2002 May 15;168(10):5024-31
references.pmid: 11994454
references.citation: Histopathology. 2015 Jan;66(2):192-200
references.pmid: 24805087
references.citation: PLoS One. 2014;9(9):e107530
references.pmid: 25202904
references.citation: Sci STKE. 2003 Mar 4;2003(172):RE5
references.pmid: 12621150
references.citation: Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):742-7
references.pmid: 15662024
references.citation: J Clin Invest. 2013 Mar;123(3):1157-75
references.pmid: 23434594
references.citation: Cancer Res. 2008 Nov 15;68(22):9125-30
references.pmid: 19010882
references.citation: J Biol Chem. 2009 May 29;284(22):15215-23
references.pmid: 19324870
references.citation: Oncogene. 2014 Aug 21;33(34):4307-15
references.pmid: 24037530
references.citation: Cell Cycle. 2012 Dec 1;11(23):4352-65
references.pmid: 23111389
references.citation: Hepatology. 2014 Jan;59(1):58-70
references.pmid: 23857333
references.citation: PLoS One. 2014;9(2):e87780
references.pmid: 24523873
references.citation: Cancer Treat Rev. 2004 Apr;30(2):193-204
references.pmid: 15023437
references.citation: Cancer Res. 1998 Jan 1;58(1):29-33
references.pmid: 9426052
references.citation: Curr Cancer Drug Targets. 2013 Mar;13(3):234-44
references.pmid: 23297823
references.citation: Cancer Biol Ther. 2008 Jul;7(7):1073-8
references.pmid: 18437054
references.citation: Curr Pharm Des. 2013;19(5):895-906
references.pmid: 22973958
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1075-83
references.pmid: 20085938
references.citation: Nature. 2004 Sep 16;431(7006):350-5
references.pmid: 15372042
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5
references.pmid: 11572954
references.citation: Brain Pathol. 2009 Jan;19(1):112-20
references.pmid: 19076776
references.citation: J Biol Chem. 2003 Apr 4;278(14):12361-6
references.pmid: 12517744
references.citation: Leukemia. 2003 Nov;17(11):2157-67
references.pmid: 12931221
references.citation: Mol Cancer. 2007;6:60
references.pmid: 17894887
references.citation: Genet Test Mol Biomarkers. 2014 May;18(5):366-70
references.pmid: 24606013
references.citation: J Immunol. 2004 May 1;172(9):5522-7
references.pmid: 15100294
references.citation: Mol Cell. 2007 Mar 23;25(6):917-31
references.pmid: 17386267
references.citation: Oncogene. 2003 May 19;22(20):3113-22
references.pmid: 12789288
references.citation: Clin Cancer Res. 2009 Aug 1;15(15):4799-805
references.pmid: 19638457
references.citation: J Biol Chem. 2013 Jun 7;288(23):16274-81
references.pmid: 23603907
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Biophys J. 2013 Feb 5;104(3):613-21
references.pmid: 23442912
references.citation: Cell Cycle. 2005 Jul;4(7):908-13
references.pmid: 15917664
references.citation: Trends Endocrinol Metab. 2008 Aug;19(6):223-30
references.pmid: 18511290
references.citation: Carcinogenesis. 2013 Apr;34(4):893-901
references.pmid: 23276799
references.citation: Nat Rev Cancer. 2006 Nov;6(11):857-66
references.pmid: 17060945
references.citation: Annu Rev Biochem. 1998;67:481-507
references.pmid: 9759495
references.citation: Anticancer Res. 2014 Aug;34(8):4569-75
references.pmid: 25075101
references.citation: Cancer Biol Ther. 2011 Aug 15;12(4):253-9
references.pmid: 21613825
references.citation: Curr Cancer Drug Targets. 2008 Feb;8(1):2-6
references.pmid: 18288938
references.citation: Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):505-15
references.pmid: 18565348
references.citation: PLoS One. 2013;8(12):e83312
references.pmid: 24376685
references.citation: Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
references.pmid: 16166262
references.citation: Oncogene. 1998 Jan 29;16(4):541-5
references.pmid: 9484844
references.citation: Blood. 2010 Nov 18;116(20):4240-50
references.pmid: 20671123
references.citation: Oncotarget. 2014 Jul 15;5(13):4834-44
references.pmid: 24947616
references.citation: BMC Cancer. 2014;14:526
references.pmid: 25046975
references.citation: PLoS One. 2010;5(7):e11171
references.pmid: 20625400
references.citation: Science. 2006 Jan 6;311(5757):36-7
references.pmid: 16400132